Virologica Sinica

, Volume 32, Issue 6, pp 454–464 | Cite as

Recent advances in the study of hepatitis B virus covalently closed circular DNA

Review
  • 114 Downloads

Abstract

Chronic hepatitis B infection is caused by hepatitis B virus (HBV) and a total cure is yet to be achieved. The viral covalently closed circular DNA (cccDNA) is the key to establish a persistent infection within hepatocytes. Current antiviral strategies have no effect on the pre-existing cccDNA reservoir. Therefore, the study of the molecular mechanism of cccDNA formation is becoming a major focus of HBV research. This review summarizes the current advances in cccDNA molecular biology and the latest studies on the elimination or inactivation of cccDNA, including three major areas: (1) epigenetic regulation of cccDNA by HBV X protein, (2) immune-mediated degradation, and (3) genome-editing nucleases. All these aspects provide clues on how to finally attain a cure for chronic hepatitis B infection.

Keywords

hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) HBx immunemediated genome-editing nucleases 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Notes

Acknowledgments

This study was supported by the Key Project of Hubei Province Natural Science Foundation (2014CFA075), the National Natural Science Foundation of China (31400153) and the Applied Basic Research Program (2015060101010033), Wuhan, China.

References

  1. Allweiss L, Dandri M. 2016. Experimental in vitro and in vivo models for the study of human hepatitis B virus infection. J Hepatol, 64: S17–S31.CrossRefPubMedGoogle Scholar
  2. Beck J, Nassal M. 2007. Hepatitis B virus replication. World J Gastroenterol, 13: 48–64.CrossRefPubMedPubMedCentralGoogle Scholar
  3. Belloni L, Pollicino T, De Nicola F, Guerrieri F, Raffa G, Fanciulli M, Raimondo G, Levrero M. 2009. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA fuction. Proc Natl Acad Sci USA, 106: 19975–19979.CrossRefPubMedPubMedCentralGoogle Scholar
  4. Cai D, Mills C, Yu W, Yan R, Aldrich CE, Saputelli JR, Mason WS, Xu X, Guo JT, Block TM, Cuconati A, Guo H. 2012. Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. Antimicrob Agents Chemother, 56: 4277–4288.CrossRefPubMedPubMedCentralGoogle Scholar
  5. Cui X, McAllister R, Boregowda R, Sohn JA, Cortes Ledesma F, Caldecott KW, Seeger C, Hu J. 2015. Does Tyrosyl DNA Phosphodiesterase-2 Play a Role in Hepatitis B Virus Genome Repair?. PLoS One, 10: e0128401.CrossRefPubMedPubMedCentralGoogle Scholar
  6. Decorsière A, Mueller H, van Breugel PC, Abdul F, Gerossier L, Beran RK, Livingston CM, Niu C, Fletcher SP, Hantz O, Strubin M. 2016. Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor. Nature, 531: 386–389.CrossRefPubMedGoogle Scholar
  7. Feng H, Hu K. 2009. Structural Characteristics and Molecular Mechanism of Hepatitis B Virus Reverse Transcriptase. Virol Sin, 24: 509–517.CrossRefGoogle Scholar
  8. Fu Y, Foden JA, Khayter C, Maeder ML, Reyon D, Joung JK, Sander JD. 2013. High-frequency off-target mutagenesis in-duced by CRISPR-Cas nucleases in human cells. Nat Biotechnol, 31: 822–826.CrossRefPubMedPubMedCentralGoogle Scholar
  9. Gao W, Hu J. 2007. Formation of hepatitis B virus covalently closed circular DNA: removal of genome-linked protein. J Virol, 81: 6164–6174.CrossRefPubMedPubMedCentralGoogle Scholar
  10. Guo L, Wang X, Ren L, Zeng M, Wang S, Weng Y, Tang Z, Wang X, Tang Y, Hu H, Li M, Zhang C, Liu C. 2014. HBx affects CUL4-DDB1 function in both positive and negative manners. Biochem Biophys Res Commun, 450: 1492–1497.CrossRefPubMedGoogle Scholar
  11. Guo H, Jiang D, Zhou T, Cuconati A, Block TM, Guo JT. 2007. Characterizat ion of the intracellular deproteinized relaxed c ircular DNA of hepatit is B virus: an intermediate of covalently closed circular DNA formation. J Virol, 81: 12472–12484.CrossRefPubMedPubMedCentralGoogle Scholar
  12. Guo H, Mao R, Block TM, Guo JT. 2010. Production and function of the cytoplasmic deproteinized relaxed circular DNA of hepadnaviruses. J Virol, 84: 387–396.CrossRefPubMedGoogle Scholar
  13. Guo X, Chen P, Hou X, Xu W, Wang D, Wang TY, Zhang L, Zheng G, Gao ZL, He CY, Zhou B, Chen ZY. 2016. The recombined cccDNA produced using minicircle technology mimicked HBV genome in structure and function closely. Scientific Reports, 6: 25552.CrossRefPubMedPubMedCentralGoogle Scholar
  14. Hayes CN, Chayama K. 2016. HBV culture and infections systems. Hepatol Int, 10: 559–566.CrossRefPubMedGoogle Scholar
  15. Hong X, Kim ES, Guo H. 2017. Epigenetic Regulation of Hepatitis B Virus Covalently Closed Circular DNA: Implications for Epigenetic Therapy against Chronic Hepatitis B. Hepatology. doi: 10.1002/hep.29479.Google Scholar
  16. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, Tobias H. 2008. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol, 6: 1315–1341.CrossRefPubMedGoogle Scholar
  17. Kitamura K, Wang Z, Chowdhury S, Simadu M, Koura M, Muramatsu M. 2013. Uracil DNA Glycosylase Counteracts APOBEC3G-Induced Hypermutation of Hepatitis B Viral Genomes: Excision Repair of Covalently Closed Circular DNA. PLoS Pathog, 9: e1003361.CrossRefPubMedPubMedCentralGoogle Scholar
  18. Königer C, Wingert I, Marsmann M, Rösler C, Beck J, Nassal M. 2014. Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses. Proc Natl Acad Sci USA, 111: E4244–E4253.CrossRefPubMedPubMedCentralGoogle Scholar
  19. Ladner SK, Otto MJ, Barker CS, Zaifert K, Wang GH, Guo JT, Seeger C, King RW. 1997. Inducible Expression of Human Hepatitis B Virus (HBV) in Stably Transfected Hepatoblastoma Cells: a Novel System for Screening Potential Inhibitors of HBV Replication. Antimicrob Agents Chemother, 41: 1715–1720.PubMedPubMedCentralGoogle Scholar
  20. Li F, Cheng L, Murphy CM, Reszka-Blanco NJ, Wu Y, Chi L, Hu J, Su L. 2016. Minicircle HBV cccDNA with a Gaussia luciferase reporter for investigating HBV cccDNA biology and developing cccDNA-targeting drugs. Scientific Reports, 6: 36483.CrossRefPubMedPubMedCentralGoogle Scholar
  21. Lin SR, Yang HC, Kuo YT, Liu CJ, Yang TY, Sung KC, Lin YY, Wang HY, Wang CC, Shen YC, Wu FY, Kao JH, Chen DS, Chen PJ. 2014. The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo. Molecular therapy Nucleic acids, 3: e186.CrossRefPubMedPubMedCentralGoogle Scholar
  22. Lilley CE, Schwartz RA,Weitzman MD. 2007. Using or abusing: viruses and the cellular DNA damage response. Trends Microbiol, 15: 119–126.CrossRefPubMedGoogle Scholar
  23. Lin GG, Zhang K, Li JM. 2015. Application of CRISPR/Cas9 Technology to HBV. Int J Mol Sci, 16: 26077–26086.CrossRefPubMedPubMedCentralGoogle Scholar
  24. Liu Y, Li J, Chen J, Li Y, Wang W, Du X, Song W, Zhang W, Lin L, Yuan Z. 2015. Hepatitis B virus polymerase disrupts K63-linked ubiquitination of STING to block innate cytosolic DNAsensing pathways. J Virol, 89: 2287–2300.CrossRefPubMedGoogle Scholar
  25. Luangsay S, Gruffaz M, Isorce N, Testoni B, Michelet M, Faure-Dupuy S, Maadadi S, Ait-Goughoulte M, Parent R, Rivoire M, Javanbakht H, Lucifora J, Durantel D. 2015. Zoulim F Early inhibition of hepatocyte innate responses by hepatitis B virus. J Hepatol, 63: 1314–1322.CrossRefPubMedGoogle Scholar
  26. Lucifora J, Protzer U. 2016. Attacking hepatitis B virus cccDNA- The holy grail to hepatitis B cure. J Hepatol, 64: S41–S48.CrossRefPubMedGoogle Scholar
  27. Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, Sprinzl MF, Koppensteiner H, Makowska Z, Volz T, Remouchamps C, Chou WM, Thasler WE, Hüser N, Durantel D, Liang TJ, Münk C, Heim MH, Browning JL, Dejardin E, Dandri M, Schindler M, Heikenwalder M, Protzer U. 2014. Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA. Science, 343: 1221–1228.CrossRefPubMedGoogle Scholar
  28. Luo X, Huang Y, Chen Y, Tu Z, Hu J, Tavis JE, Huang A, Hu Y. 2016. Association of Hepatitis B Virus Covalently Closed Circular DNA and Human APOBEC3B in Hepatitis B Virus-Related Hepatocellular Carcinoma. PLoS One, 11: e0157708.CrossRefPubMedPubMedCentralGoogle Scholar
  29. Murphy CM, Xu Y, Li F, Nio K, Reszka-Blanco N, Li X, Wu Y, Yu Y, Xiong Y, Su L. 2016. Hepatitis B Virus X protein promotes degradation of SMC5/6 to enhance HBV replication. Cell Rep, 16: 2846–2854.CrossRefPubMedPubMedCentralGoogle Scholar
  30. Nassal M. 2015. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut, 64: 1972–1984.CrossRefPubMedGoogle Scholar
  31. Ni Y, Lempp FA, Mehrle S, Nkongolo S, Kaufman C, Fälth M, Stindt J, Königer C, Nassal M, Kubitz R, Sültmann H, Urban S. 2014. Hepatitis B and D viruses exploit sodium taurocholate cotransporting polypeptide for species-specific entry into hepatocytes. Gastroenterology, 146: 1070–1083.CrossRefPubMedGoogle Scholar
  32. Niu C, Livingston CM, Li L, Beran RK, Daffis S, Ramakrishnan D, Burdette D, Peiser L, Salas E, Ramos H, Yu M, Cheng G, Strubin M, Delaney Iv WE, Fletcher SP. 2017. The Smc5/6 Complex Restricts HBV when Localized to ND10 without Inducing an Innate Immune Response and Is Counteracted by the HBV X Protein Shortly after Infection. PLoS One, 12: e0169648.CrossRefPubMedPubMedCentralGoogle Scholar
  33. Ogi T, Lehmann AR. 2006. The Y-family DNA polymerase kappa (pol kappa) functions in mammalian nucleotide-excision repair. Nat Cell Biol, 8: 640–642.CrossRefPubMedGoogle Scholar
  34. Ogi T, Limsirichaikul S, Overmeer RM, Volker M, Takenaka K, Cloney R, Nakazawa Y, Niimi A, Miki Y, Jaspers NG, Mullenders LH, Yamashita S, Fousteri MI, Lehmann AR. 2010. Three DNA polymerases, recruited by different mechanisms, carry out NER repair synthesis in human cells. Mol Cell, 37: 714–727.CrossRefPubMedGoogle Scholar
  35. Palumbo GA, Scisciani C, Pediconi N, Lupacchini L, Alfalate D, Guerrieri F, Calvo L, Salerno D, Di Cocco S, Levrero M, Belloni L. 2015. IL6 inhibits HBV transcription by targeting the epigenetic control of the nuclear cccDNA minichromosome. PLoS One, 10: e0142599.CrossRefPubMedPubMedCentralGoogle Scholar
  36. Pommier Y, Huang SY, Gao R, Das BB, Murai J, Marchand C. 2014. Tyrosyl-DNA-phosphodiesterases (TDP1 and TDP2). DNA Repair (Amst), 19: 114–129.CrossRefGoogle Scholar
  37. Qi Y, Gao Z, Xu G, Peng B, Liu C, Yan H, Yao Q, Sun G, Liu Y, Tang D, Song Z, He W, Sun Y, Guo JT, Li W. 2016. DNA Polymerase ? Is a Key Cellular Factor for the Formation of Covalently Closed Circular DNA of Hepatitis B Virus. PLoS Pathog, 12: e1005893.CrossRefPubMedPubMedCentralGoogle Scholar
  38. Qi Z, Li G, Hu H, Yang C, Zhang X, Leng Q, Xie Y, Yu D, Zhang X, Gao Y, Lan K, Deng Q. 2014. Recombinant covalently closed circular hepatitis B virus DNA induces prolonged viral Persistence in Immunocompetent Mice. J Virol, 88: 8045–8056.CrossRefPubMedPubMedCentralGoogle Scholar
  39. Ramanan V, Shlomai A, Cox DB, Schwartz RE, Michailidis E, Bhatta A, Scott DA, Zhang F, Rice CM, Bhatia SN. 2015. CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus. Sci Rep, 5: 10833.CrossRefPubMedPubMedCentralGoogle Scholar
  40. Revill P, Locarnini S. 2016. Antiviral strategies to eliminate hepatitis B virus covalently closed circular DNA (cccDNA). Curr Opin Pharmacol, 30: 144–150.CrossRefPubMedGoogle Scholar
  41. Rivière L, Gerossier L, Ducroux A, Dion S, Deng Q, Michel ML, Buendia MA, Hantz O, Neuveut C. 2015. HBX relieves chromatin- mediated transcriptional repression of hepatitis B viral cccDNA involving SETDB1 histone methyltransferase. J Hepatol, 63: 1093–1102.CrossRefPubMedGoogle Scholar
  42. Schubeler D. 2015. Function and information content of DNA methylation. Nature, 517: 321–326.CrossRefPubMedGoogle Scholar
  43. Schreiner S, Nassal M. 2017. A Role for the Host DNA Damage Response in Hepatitis B Virus cccDNA Formation—and Beyond?. Viruses, 9: 125.CrossRefPubMedCentralGoogle Scholar
  44. Schwartz RE, Fleming HE, Khetani SR, Bhatia SN. 2014. Pluripotent stem cell-derived hepatocyte-like cells. Biotechnol Adv, 32: 504–513.CrossRefPubMedPubMedCentralGoogle Scholar
  45. Seeger C, Sohn JA. 2016. Complete Spectrum of CRISPR/Cas9- induced Mutations on HBV cccDNA. Mol Ther, 24: 1258–1266.CrossRefPubMedPubMedCentralGoogle Scholar
  46. Seeger C, Sohn JA. 2014. Targeting hepatitis B virus cccDNA using CRISPR/Cas9. Mol Ther Nucl Acids, 3: e216.CrossRefGoogle Scholar
  47. Shimura S, Watashi K, Fukano K, Peel M, Sluder A, Kawai F, Iwamoto M, Tsukuda S, Takeuchi JS, Miyake T, Sugiyama M, Ogasawara Y, Park SY, Tanaka Y, Kusuhara H, Mizokami M, Sureau C, Wakita T. 2017. Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity. J Hepatol, 66: 685–692.CrossRefPubMedGoogle Scholar
  48. Si-Tayeb K, Noto FK, Nagaoka M, Li J, Battle MA, Duris C, North PE, Dalton S, Duncan SA. 2010. Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells. Hepatology, 51: 297–305.CrossRefPubMedPubMedCentralGoogle Scholar
  49. Takahashi K, Yamanaka S. 2006. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126: 663–676.CrossRefPubMedGoogle Scholar
  50. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. 2007. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131: 861–872.CrossRefPubMedGoogle Scholar
  51. Touboul T, Hannan NR, Corbineau S, Martinez A, Martinet C, Branchereau S, Mainot S, Strick-Marchand H, Pedersen R, Di Santo J, Weber A, Vallier L. 2010. Generation of functional hepatocytes from human embryonic stem cells under chemically defined conditions that recapitulate liver development. Hepatology, 51: 1754–1765.CrossRefPubMedGoogle Scholar
  52. Vivekanandan P, Daniel HDJ, Kannangai R, Martinez-Murillo F, Torbenson M. 2010. Hepatitis B virus replication induces methylation of both host and viral DNA. J. Virol, 84: 4321–4329.CrossRefPubMedPubMedCentralGoogle Scholar
  53. Wieland SF. 2015. The chimpanzee model for hepatitis B virus infection. Cold Spring Harb Perspect Med, 5. pii: a021469.CrossRefPubMedPubMedCentralGoogle Scholar
  54. Wood RD., Mitchell M., Sgouros J., Lindahl T 2001. Human DNA repair genes. Science, 291: 1284–1289.CrossRefPubMedGoogle Scholar
  55. Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, Fu L, Song M, Chen P, Gao W, Ren B, Sun Y, Cai T, Feng X, Sui J, Li W. 2012. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife, 1: e00049.CrossRefPubMedPubMedCentralGoogle Scholar
  56. Yan Z, Zeng J, Yu Y, Xiang K, Hu H, Zhou X, Gu L, Wang L, Zhao J, Young JA, Gao L. 2017. HBV circle: A novel tool to investigate hepatitis B virus covalently closed circular DNA. J Hepatol, pii: S0168-8278(17)30072-7.Google Scholar
  57. Yang D, Zuo C, Wang X, Meng X, Xue B, Liu N, Yu R, Qin Y, Gao Y, Wang Q, Hu J, Wang L, Zhou Z, Liu B, Tan D, Guan Y, Zhu H. 2014. Complete replication of hepatitis B virus and hepatitis C virus in a newly developed hepatoma cell line. Proc Natl Acad Sci USA, 111: E1264–E1273.CrossRefPubMedPubMedCentralGoogle Scholar
  58. Yang L, Lu M. 2017. Small molecule inhibitors of hepatitis B virus nucleocapsid assembly: a new approach to treat chronic HBV infection. Curr Med Chem, doi: 10.2174/09298673246661 70704121800.Google Scholar
  59. Zhen S, Hua L, Liu YH, Gao LC, Fu J, Wan DY, Dong LH, Song HF, Gao X. 2015. Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus. Gene Ther, 22: 404–412.CrossRefPubMedGoogle Scholar
  60. Zoulim F, Locarnini S. 2009. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology, 137: 1593–1608.e1-2.CrossRefPubMedGoogle Scholar

Copyright information

© Wuhan Institute of Virology, CAS and Springer Nature Singapore Pte Ltd. 2017

Authors and Affiliations

  1. 1.Sino-German Biomedical Center, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei Provincial Cooperative Innovation Center of Industrial Fermentation, National “111” Center for Cellular Regulation and Molecular PharmaceuticsHubei University of TechnologyWuhanChina

Personalised recommendations